Treatment-related adverse events of antibody drug-conjugates in clinical trials
Abstract Background Antibody–drug conjugates (ADCs) aim to enhance the therapeutic index of cytotoxic agents but can cause unexpected toxicities. This study evaluated adverse events (AEs) from phase 1 trials at The Royal Marsden Drug Development Unit (DDU) over a decade and pivotal phase 2 and 3 tri...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-025-01720-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849769232664887296 |
|---|---|
| author | Harold Nathan Tan Marta Ascanio Morcillo Juanita Lopez Anna Minchom Adam Sharp Alec Paschalis Georgina Silva-Fortes Bindu Raobaikady Udai Banerji |
| author_facet | Harold Nathan Tan Marta Ascanio Morcillo Juanita Lopez Anna Minchom Adam Sharp Alec Paschalis Georgina Silva-Fortes Bindu Raobaikady Udai Banerji |
| author_sort | Harold Nathan Tan |
| collection | DOAJ |
| description | Abstract Background Antibody–drug conjugates (ADCs) aim to enhance the therapeutic index of cytotoxic agents but can cause unexpected toxicities. This study evaluated adverse events (AEs) from phase 1 trials at The Royal Marsden Drug Development Unit (DDU) over a decade and pivotal phase 2 and 3 trials leading to FDA registration, correlating AEs with ADC components such as target, antibody, linker, payload, and Drug-to-Antibody Ratio (DAR). Methods We performed a retrospective cohort analysis of patients treated with ADCs in phase 1 trials (January 2014 to January 2024) compared to published phase 2–3 trials of FDA-approved ADCs. Univariate and multivariate logistic regression analyzed ADC components and treatment toxicities. Results One hundred thirty one phase 1 trial patients and 2666 phase 2–3 trial participants were included. High incidences of any-grade treatment-related AEs were observed (89% in phase 1, 93% in phase 2–3), with 58% experiencing grade 3 or higher toxicities in phase 1 and 46% in later phases. Major AEs included fatigue, hematologic toxicities, nausea/vomiting, ocular toxicities, and peripheral neuropathy. Antibody targets were linked to neuropathy, non-cleavable linkers to ocular, pulmonary, and hematologic toxicities, and tubulin-binding payloads to peripheral neuropathy. ADCs with DAR > 4 were associated with higher pulmonary and hematologic AEs. Conclusion Despite their design to minimize toxicity, ADCs were linked to significant AEs. Specific ADC components may contribute to distinct toxicities, necessitating more robust trial data to inform future ADC design. Graphical Abstract |
| format | Article |
| id | doaj-art-daf8c53d90374be8979d8a3daeb8fa40 |
| institution | DOAJ |
| issn | 1756-8722 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj-art-daf8c53d90374be8979d8a3daeb8fa402025-08-20T03:03:29ZengBMCJournal of Hematology & Oncology1756-87222025-07-0118111110.1186/s13045-025-01720-3Treatment-related adverse events of antibody drug-conjugates in clinical trialsHarold Nathan Tan0Marta Ascanio Morcillo1Juanita Lopez2Anna Minchom3Adam Sharp4Alec Paschalis5Georgina Silva-Fortes6Bindu Raobaikady7Udai Banerji8The Royal Marsden HospitalThe Royal Marsden HospitalThe Royal Marsden HospitalThe Royal Marsden HospitalThe Royal Marsden HospitalThe Royal Marsden HospitalThe Royal Marsden HospitalThe Royal Marsden HospitalThe Royal Marsden HospitalAbstract Background Antibody–drug conjugates (ADCs) aim to enhance the therapeutic index of cytotoxic agents but can cause unexpected toxicities. This study evaluated adverse events (AEs) from phase 1 trials at The Royal Marsden Drug Development Unit (DDU) over a decade and pivotal phase 2 and 3 trials leading to FDA registration, correlating AEs with ADC components such as target, antibody, linker, payload, and Drug-to-Antibody Ratio (DAR). Methods We performed a retrospective cohort analysis of patients treated with ADCs in phase 1 trials (January 2014 to January 2024) compared to published phase 2–3 trials of FDA-approved ADCs. Univariate and multivariate logistic regression analyzed ADC components and treatment toxicities. Results One hundred thirty one phase 1 trial patients and 2666 phase 2–3 trial participants were included. High incidences of any-grade treatment-related AEs were observed (89% in phase 1, 93% in phase 2–3), with 58% experiencing grade 3 or higher toxicities in phase 1 and 46% in later phases. Major AEs included fatigue, hematologic toxicities, nausea/vomiting, ocular toxicities, and peripheral neuropathy. Antibody targets were linked to neuropathy, non-cleavable linkers to ocular, pulmonary, and hematologic toxicities, and tubulin-binding payloads to peripheral neuropathy. ADCs with DAR > 4 were associated with higher pulmonary and hematologic AEs. Conclusion Despite their design to minimize toxicity, ADCs were linked to significant AEs. Specific ADC components may contribute to distinct toxicities, necessitating more robust trial data to inform future ADC design. Graphical Abstracthttps://doi.org/10.1186/s13045-025-01720-3ADCsAEsClinical trials |
| spellingShingle | Harold Nathan Tan Marta Ascanio Morcillo Juanita Lopez Anna Minchom Adam Sharp Alec Paschalis Georgina Silva-Fortes Bindu Raobaikady Udai Banerji Treatment-related adverse events of antibody drug-conjugates in clinical trials Journal of Hematology & Oncology ADCs AEs Clinical trials |
| title | Treatment-related adverse events of antibody drug-conjugates in clinical trials |
| title_full | Treatment-related adverse events of antibody drug-conjugates in clinical trials |
| title_fullStr | Treatment-related adverse events of antibody drug-conjugates in clinical trials |
| title_full_unstemmed | Treatment-related adverse events of antibody drug-conjugates in clinical trials |
| title_short | Treatment-related adverse events of antibody drug-conjugates in clinical trials |
| title_sort | treatment related adverse events of antibody drug conjugates in clinical trials |
| topic | ADCs AEs Clinical trials |
| url | https://doi.org/10.1186/s13045-025-01720-3 |
| work_keys_str_mv | AT haroldnathantan treatmentrelatedadverseeventsofantibodydrugconjugatesinclinicaltrials AT martaascaniomorcillo treatmentrelatedadverseeventsofantibodydrugconjugatesinclinicaltrials AT juanitalopez treatmentrelatedadverseeventsofantibodydrugconjugatesinclinicaltrials AT annaminchom treatmentrelatedadverseeventsofantibodydrugconjugatesinclinicaltrials AT adamsharp treatmentrelatedadverseeventsofantibodydrugconjugatesinclinicaltrials AT alecpaschalis treatmentrelatedadverseeventsofantibodydrugconjugatesinclinicaltrials AT georginasilvafortes treatmentrelatedadverseeventsofantibodydrugconjugatesinclinicaltrials AT binduraobaikady treatmentrelatedadverseeventsofantibodydrugconjugatesinclinicaltrials AT udaibanerji treatmentrelatedadverseeventsofantibodydrugconjugatesinclinicaltrials |